Immuneering — Third Quarter 2026 Earnings Summary

Immuneering Corporation reported a net loss of $24.2 million for the third quarter ended September 30, 2026, with cash and marketable securities totaling $166.1 million. The company extended follow-up in its Phase 2 pancreatic cancer trial as patients on the atebimetinib combination therapy are living longer than projected, with updated data expected in the first half of 2027. Enrollment for the pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule, prompting an expansion of the target to 570 patients and a potential acceleration of the mid-2028 topline data readout. Based on current operating plans, the company expects its cash runway to extend into the fourth quarter of 2028.